Satellos Bioscience (TSE:MSCL) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Satellos Bioscience is launching an overnight marketed public offering of its common shares to fund the advancement of its Phase 2 clinical development and cover general corporate expenses. The offering, led by Bloom Burton Securities Inc., is set to close around December 20, 2024, pending regulatory approvals.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.